Executive Summary of 2023 International Conference of the Korean Dementia Association (IC-KDA 2023): A Report From the Academic Committee of the Korean Dementia Association

키워드

참고문헌 (39)

1. Byrd AL, "Infectious disease. Adapting Koch’s postulates", Science, 351, pp.224~226 (2016)
2. Dominy SS, "Porphyromonas gingivalis in Alzheimer’s disease brains : evidence for disease causation and treatment with small-molecule inhibitors", Sci Adv, 5, pp.eaau3333~ (2019)
3. Park SH, "Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection", Aging(Albany NY), 14, pp.6449~6466 (2022)
4. Shi Y, "ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy", Nature, 549, pp.523~527 (2017)
5. Seo DO, "ApoE isoform-and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy", Science, 379, pp.eadd1236~ (2023)
6. Xiong J, "C", EBPβ, Neurosci Bull, pp.2023, 39[DOI]
7. Xia Y, "Neuronal C", EBPβ, Sci Adv, pp.2022, 8[DOI]
8. Hu Y, "Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment", JAMA Netw Open, 5, pp.e228392~ (2022)
9. Fogelman I, "Independent study demonstrates amyloid probability score accurately indicates amyloid pathology", Ann Clin Transl Neurol, 10, pp.765~778 (2023)
10. Liu HC, "Investigation of the number of tests required for assaying plasma biomarkers associated with Alzheimer’s disease using immunomagnetic reduction", Neurol Ther, 10, pp.1015~1028 (2021)
11. Chiu PY, "Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia", Sci Rep, 12, pp.17919~ (2022)
12. Wang MJ, "Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease", Alzheimers Res Ther, 9, pp.98~ (2017)
13. Babapour Mofrad R, "Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status", Alzheimers Res Ther, 13, pp.133~ (2021)
14. Cummings J, "Defining disease modifying therapy for Alzheimer’s disease", J Prev Alzheimers Dis, 4, pp.109~115 (2017)
15. Van Dam D, "Drug discovery in dementia : the role of rodent models", Nat Rev Drug Discov, 5, pp.956~970 (2006)
16. Cummings J, "Alzheimer’s disease drug development pipeline : 2022", Alzheimers Dement(N Y), 8, pp.e12295~ (2022)
17. Salloway S, "Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease", JAMA Neurol, 79, pp.13~21 (2022)
18. Esmaeili A, "Recent approaches in regenerative medicine in the fight against neurodegenerative disease", Brain Res, 1825, pp.148688~ (2024)
19. Kaur R, "Role of Microbes in Sustainable Development: Human Health and Diseases", pp.193~232 (2023), Springer Nature Singapore
20. Purushotham SS, "Astrocytic modulation of neuronal signalling", Front Netw Physiol, 3, pp.1205544~ (2023)
21. Verhoog QP, "Astrocytes as guardians of neuronal excitability : mechanisms underlying epileptogenesis", Front Neurol, 11, pp.591690~ (2020)
22. Berron D, "Feasibility of digital memory assessments in an unsupervised and remote study setting", Front Digit Health, 4, pp.892997~ (2022)
23. Kwak S, "Utility of machine learning approach with neuropsychological tests in predicting functional impairment of Alzheimer’s disease", J Alzheimers Dis, 85, pp.1357~1372 (2022)
24. Staffaroni AM, "A remote smartphone cognitive testing battery for frontotemporal dementia : completion rate, reliability, and validity", Alzheimers Dement, 17, pp.e056136~ (2021)
25. Rankin KP, "Brain networks supporting social cognition in dementia", Curr Behav Neurosci Rep, 7, pp.203~211 (2020)
26. Dimitriou T, "The assessment of the socioemotional disorder in neurodegenerative diseases with the Revised Self-Monitoring Scale(RSMS)", J Clin Med, 11, pp.7375~ (2022)
27. Rijpma MG, "Semantic knowledge of social interactions is mediated by the hedonic evaluation system in the brain", Cortex, 161, pp.26~37 (2023)
28. Rohrer JD, "The frontotemporal dementia prevention initiative : linking together genetic frontotemporal dementia cohort studies", Adv Exp Med Biol, 1281, pp.113~121 (2021)
29. Boeve B, "The longitudinal evaluation of familial frontotemporal dementia subjects protocol : Framework and methodology", Alzheimers Dement, 16, pp.22~36 (2020)
30. Ullgren A, "Altered plasma protein profiles in genetic FTD-a GENFI study", Mol Neurodegener, 18, pp.85~ (2023)
31. Rojas JC, "Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration", Neurology, 96, pp.e2296~e2312 (2021)
32. Gendron TF, "Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders", Cell Rep Med, 3, pp.100607~ (2022)
33. Taylor JC, "Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research", Alzheimers Dement(Amst), 15, pp.e12423~ (2023)
34. Barker MS, "Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia", Cortex, 139, pp.99~115 (2021)
35. Seo JS, "Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy", Exp Mol Med, 49, pp.e333~ (2017)
36. Lee SJ, "Protein aggregate spreading in neurodegenerative diseases : problems and perspectives", Neurosci Res, 70, pp.339~348 (2011)
37. Lee J, "Targeted degradation of α-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology", Mol Neurodegener, 18, pp.41~ (2023)
39. Kao CS, "Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS", Nat Commun, 11, pp.5304~ (2020)

관련 논문AI추천